Technology | 2018.03.15
New Article from Asymmetrex’s Director Predicts Increasing Investment by Pharma in Regenerative Medicine Development
Although more investment by major pharmaceutical companies would accelerate progress in regenerative medicine, in recent years, regenerative medicine initiatives have experienced a tepid reception by Big Pharma. In an editorial article appearing today in Pharmaceutical Manufacturing, James Sherley, founder and director of stem cell biotechnology tools company Asymmetrex, offers an explanation and a solution for Pharma’s hesitancy to invest more in regenerative medicine development.
(PRWeb March 15, 2018)
Read the full story at http://www.prweb.com/releases/2018/03/prweb15321270.htm
For more information, please visit
http://www.prweb.com/releases/2018/03/prweb15321270.htm
